Immunotherapy for colorectal cancer: current views and perspectives
Пономарева О.В.1, Рыспаева Д.Э.2, Сивак Л.А.3
- 1P.L. Shupyk National Medical Academy of Postgraduate Education, Kyiv
- 2Branch «Medical Center «Cyber Clinic Spizhenko» (LLC «Company Adonis»), Kyiv
- 3National Cancer Institute, Kyiv
Summary. The emergence of immunotherapeutic agents has opened the way to a new era in the treatment of many malignant tumors. Immune checkpoint inhibitors, such as anti-PD1 and anti-PD-L1, are the most widely used in the treatment of a different cancer types. In the era of precision medicine, the recent consensus on the molecular classification of colorectal cancer paved the way for a personalized approach to treating this disease. Patients with the CMS1 colorectal cancer subtype (mainly MSI-H) have been found to be the best candidates for immunotherapy, and clinical trials demonstrate unprecedented results that lead to the approval of pembrolizumab and nivolumab for treatment of metastatic colorectal cancer. Currently, many clinical trials are continuing with the use of new combined regimens, including drugs of various groups.
Leave a comment